BRIEF published on 01/08/2025 at 14:35, 1 year 7 months ago Santé Canada approuve le médicament biosimilaire FYB202/Otulfi® de Formycon Formycon Ustekinumab Coûts Des Soins De Santé Biosimilaire Approbation Du Canada
PRESS RELEASE published on 01/08/2025 at 14:30, 1 year 7 months ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 1 year 8 months ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
BRIEF published on 12/11/2024 at 16:31, 1 year 8 months ago Formycon AG maintient de solides perspectives de croissance dans un contexte de marché difficile Formycon AG Baisse Des Revenus Approbation De La FDA Biosimilaires Lancement De Stelara
PRESS RELEASE published on 12/11/2024 at 16:26, 1 year 8 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 1 year 8 months ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
BRIEF published on 12/09/2024 at 06:35, 1 year 8 months ago MS Pharma va commercialiser FYB202 dans la région MENA Formycon AG MS Pharma Région MENA FYB202 Biosimilaires
PRESS RELEASE published on 12/09/2024 at 06:30, 1 year 8 months ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 1 year 8 months ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
BRIEF published on 12/05/2024 at 13:00, 1 year 8 months ago Formycon rejoint le SDAX de la Bourse allemande Stratégie De Marché SDAX Formycon Biosimilaires Bourse Allemande
Published on 08/17/2026 at 22:30, 2 hours 21 minutes ago Matador Technologies Amends Convertible Note Facility to Expand At the Market Capacity and Commit a Fixed Share of Proceeds to Bitcoin
Published on 08/17/2026 at 21:00, 3 hours 51 minutes ago Taranis Announces New Critical Minerals By-Product Findings at the Thor and Ajax Mines
Published on 08/17/2026 at 15:00, 9 hours 51 minutes ago Norsemont Appoints Ariel Tepperman to Its Board
Published on 08/17/2026 at 14:30, 10 hours 21 minutes ago Alset AI Completes Sale of 9.9% Interest in Lyken AI Computing to FingerMotion
Published on 08/17/2026 at 19:00, 5 hours 51 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 10 AOUT 2026 au 14 AOUT 2026
Published on 08/17/2026 at 17:50, 7 hours 1 minute ago EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG
Published on 08/17/2026 at 19:45, 5 hours 6 minutes ago Aéroports de Paris S.A - July 2026 traffic figures
Published on 08/17/2026 at 19:45, 5 hours 6 minutes ago Aéroports de Paris S.A - Trafic du mois de juillet 2026
Published on 08/17/2026 at 17:40, 7 hours 11 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 10 au 14 août 2026 dans le cadre du programme de rachat d’actions.
